Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Novartis 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Novartis 2Q11

Alcon, new products, generics and currency flux help boost sales

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Novartis 2Q

2Q Revenues: $14.9 billion (+27%)

2Q Earnings: $2.7 billion (+12%)

YTD Revenues: $28.9 billion (+21%)

YTD Earnings: $5.5 billion (+3%)

Comments: Revenues were up 19% in constant currencies (c.c.) for 2Q11 and +16% YTD. Pharma revenues were up 10% (+2% c.c.) to $8.3 billion in 2Q, with recently launched products contributing $2.3 billion (+34% c.c.). Alcon revenues were up 12% (6% c.c.) to $2.6 billion. Sandoz (generic) revenue rose 25% (16% c.c.) to $2.5 billion. For the YTD, pharma revenues were up 8% (3% c.c.) to $16.0 billion, with $4.3 billion of that coming from recently launched products. Vaccine sales plummeted in both 2Q and YTD, a result of inflated H1N1 revenues from the previous year. Overall sales in emerging markets rose 27% (19% c.c.) to $1.5 billion in 2Q11.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters